8-K: Vaxart Receives Lift Notice from ATI, Resumes Work on BARDA-Funded Project

Vaxart's BARDA-funded project resumes after receiving a lift notice from Advanced Technology International (ATI), allowing the company to restart activities and discussions with BARDA.

Summary

• Vaxart received a stop work order from ATI on February 21, 2025, regarding its project agreement funded by BARDA.
• The stop work order halted all project efforts except for the per protocol follow-up for a 400-person cohort.
• On April 24, 2025, ATI issued a lift notice, allowing Vaxart to resume incurring costs, participating in meetings, and communicating about the project.
• Following the lift notice, Vaxart had a virtual meeting with BARDA and was authorized to proceed with screening for the 10,000 participant portion of the trial.
• Vaxart intends to reactivate field sites and screen participants for enrollment.
• The company will continue discussions with BARDA regarding the plan for dosing participants and will provide further updates as appropriate.

Sentiment

Score: 6

Explanation: The sentiment is cautiously optimistic. The lift notice is a positive development, but uncertainties remain regarding future funding and trial outcomes.

Positives

• The lift notice allows Vaxart to resume work on a significant project funded by BARDA.
• The authorization to proceed with screening for the 10,000 participant trial indicates progress in the project.
• Continued discussions with BARDA suggest ongoing collaboration and potential for further funding.

Risks

• The announcement mentions risks and uncertainties associated with Vaxart's ability to achieve milestones and deliverables under the Project Agreement.
• The company's continuing operating losses are a risk factor.
• The company's ability to secure additional funding under the Project Agreement is uncertain.
• The actions that ATI, BARDA, or another part of the United States government may take relating to the stop work order, the Lift Notice, or the Trial are uncertain.

Future Outlook

The company intends to reactivate field sites and screen participants for enrollment and will continue discussions with BARDA regarding the plan for dosing participants and will provide further updates as appropriate. The company's receipt of any additional funding of under the Project Agreement, and about any actions that ATI, BARDA, or another part of the United States government may take relating to the stop work order, the Lift Notice, or the Trial are uncertain.

Industry Context

This announcement is relevant to the pharmaceutical industry, specifically companies involved in vaccine development and partnerships with government agencies like BARDA. The resumption of the trial is a positive sign for Vaxart and could potentially impact the competitive landscape for oral vaccines.

Stakeholder Impact

• Shareholders: The resumption of the trial could positively impact shareholder value.
• Employees: The lift notice allows employees to resume work on the project.
• Customers: Successful trial outcomes could lead to the development of a new oral vaccine.

Next Steps

• Reactivate field sites.
• Screen participants for enrollment in the 10,000 participant trial.
• Continue discussions with BARDA regarding the plan for dosing participants.
• Provide further updates as appropriate.

Key Dates

Keywords

Vaxart, ATI, BARDA, Project Agreement, Clinical Trial, Stop Work Order, Lift Notice, Enrollment, Screening, Funding